| Literature DB >> 24185532 |
Birju A Shah1, James F Padbury2.
Abstract
Neonatal sepsis continues to be a common and significant health care burden, especially in very-low-birth-weight infants (VLBW<1500 g). Though intrapartum antibiotic prophylaxis has decreased the incidence of early-onset group B streptococcal infection dramatically, it still remains a major cause of neonatal sepsis. Moreover, some studies among VLBW preterm infants have shown an increase in early-onset sepsis caused by Escherichia coli. As the signs and symptoms of neonatal sepsis are nonspecific, early diagnosis and prompt treatment remains a challenge. There have been a myriad of studies on various diagnostic markers like hematological indices, acute phase reactants, C-reactive protein, procalcitonin, cytokines, and cell surface markers among others. Nonetheless, further research is needed to identify a biomarker with high diagnostic accuracy and validity. Some of the newer markers like inter α inhibitor proteins have shown promising results thereby potentially aiding in early detection of neonates with sepsis. In order to decrease the widespread, prolonged use of unnecessary antibiotics and improve the outcome of the infants with sepsis, reliable identification of sepsis at an earlier stage is paramount.Entities:
Keywords: algorithms; antibiotic prophylaxis; biomarkers; epidemiology; group B streptococcus; microbiology; neonatal sepsis; newer tests; screening
Mesh:
Substances:
Year: 2013 PMID: 24185532 PMCID: PMC3916371 DOI: 10.4161/viru.26906
Source DB: PubMed Journal: Virulence ISSN: 2150-5594 Impact factor: 5.882
Table 1. Microbial pathogens and risk factors associated with neonatal sepsis
| Neonatal sepsis | Microbial pathogens | Risk factors |
|---|---|---|
| Early-onset | • Group B streptococci | • Maternal Group B streptococcal colonization |
| Late-onset | • Coagulase-negative Staphylococci | • Prematurity |
Modified from reference 1.
Table 2. Diagnostic performance of adjunctive tests of neonatal sepsis
| Diagnostic test | Sensitivity (%) | Specificity (%) | PPVa (%) | NPVb (%) | Likelihood ratio (+) | Likelihood ratio (−) |
|---|---|---|---|---|---|---|
| WBCc | 44 | 92 | 36 | 94 | 5.5 | 0.60 |
| I:T ratiod | 54.6 | 73.7 | 2.5 | 99.2 | 2.07 | 0.61 |
| Plateletse | 22 | 99 | 60 | 93 | 2.72 | 0.78 |
| CRPf | 70–93 | 78–94 | 7–43 | 97–99.5 | 3.18–15.5 | 0.07 |
| PCTg | 83.3 | 88.6 | 83.33 | 88.57 | 6.9 | 0.188 |
| IL-6h | 87 | 93 | 76 | 97 | 12.42 | 0.14 |
| IL-8i | 91 | 93 | 91 | 97 | 13 | 0.10 |
| TNF-αj | 75 | 88 | 67 | 51 | 6.25 | 0.28 |
| IAIPk | 89.5 | 99 | 95 | 98 | 89.5 | 0.106 |
a PPV, positive predictive value; bNPV, negative predictive value; cwhite blood cell (WBC) counts ≤5000 or ≥25 000, 30 000, or 21 000 per mm3 at birth, 12–24 h and day 2 or after, respectively; dI:T ratio (ratio of immature to absolute neutrophil count) >0.2; eplatelets <150 000 cells/mm,; fC-reactive protein (CRP) >1 mg/dl; gprocalcitonin (PCT) >5.38 ng/ml at 24 h of life; hinterleukin-6 (IL-6) >100 pg/ml; iinterleukin-8 (IL-8) >300 pg/ml; jtumor necrosis factor α (TNF-α) >13 pg/ml; kinter α inhibitor proteins (IAIP) ≤177 mg/L